A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.

NCT Number	NCT07213609
Lead Sponsor	GlaxoSmithKline
Conditions	Neoplasms, Colorectal, Neoplasms
Enrollment	47 participants
Start Date	2025-10-20
Primary Completion	2028-09-28 (estimated)
Study Completion	2028-10-27 (estimated)
Updated on ClinicalTrials.gov	2026-07-21